The group's principle activities include developing, and commercializing the Professional Laboratory System(TM) platform for droplet-based microfluidics. The group's services include screening, cancer diagnostics, antibody engineering, drug formulation, therapeutic enzyme development, and RNAi screening. The group operates from United States.
